Jubilant Pharmova Ltd
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.71Jubilant Pharmova Ltd, operating within the Healthcare Services industry, demonstrates a mixed financial performance. The company shows strengths in solvency, growth, and certain financial metrics like cash earnings and book value per share. However, it faces challenges in liquidity, efficiency, and profitability, particularly concerning margins. While the company's asset and operating profit growth are positive, revenue and net income growth remain low. This suggests potential operational efficiencies but also indicates areas needing improvement to ensure sustainable financial health. The company's ability to cover interest expenses is adequate, but its dividend coverage is weak. Overall, Jubilant Pharmova exhibits a moderate financial standing with notable growth prospects, but it must address its liquidity and efficiency to achieve more robust and balanced performance.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio6.80
- Profitability Ratio4.60
- Efficiency Ratio4.67
- Coverage Ratio5.60
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBearish
- 2 HoursBearish
- 4 HoursBearish
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Health Score : 5.71Jubilant Pharmova Ltd, operating within the Healthcare Services industry, demonstrates a mixed financial performance. The company shows strengths in solvency, growth, and certain financial metrics like cash earnings and book value per share. However, it faces challenges in liquidity, efficiency, and profitability, particularly concerning margins. While the company's asset and operating profit growth are positive, revenue and net income growth remain low. This suggests potential operational efficiencies but also indicates areas needing improvement to ensure sustainable financial health. The company's ability to cover interest expenses is adequate, but its dividend coverage is weak. Overall, Jubilant Pharmova exhibits a moderate financial standing with notable growth prospects, but it must address its liquidity and efficiency to achieve more robust and balanced performance.
Overall Valuation Score
P/E RATIO (TTM)
773.08
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
38.62
P/B RATIO
2.17
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
1.82
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
13.58
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹966.35 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Growth Score : 6.00The company demonstrates strong growth in operating profit, EPS, and assets. However, revenue and net income growth are low. While the company is expanding its operations and improving profitability, revenue generation needs to keep pace to ensure sustainable growth. Focusing on strategies to boost sales and net income will be critical for long-term success.
Revenue Growth RatePoor
Operating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 0.51 | 2.48 | 6.7 | 7.92 | 14.46 |
| Operating Profit Growth Rate | -18.03 | -32.26 | 15.66 | 30.19 | 7.42 |
| Earnings Per Share (EPS) Growth | -50.49 | -114.74 | -226.37 | 988.64 | -52.51 |
| Asset Growth Rate | 12.18 | 11.18 | 3.74 | 10.99 | 23.36 |
| Net Income Growth Rate | -50.6 | -115.74 | -212.31 | 1045.21 | -52.39 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial Score : 6.80The company shows strengths in cash earnings and book value per share, but adjusted EPS is low, and dividend per share is average. Capital expenditures are also well-managed. This indicates a solid base value and cash generation ability, but there's room to improve earnings performance and returns to shareholders. Strategic capital investments could further enhance financial performance.
Adjusted Earnings Per Share (Adjusted EPS)PoorCash Earnings Per Share (Cash EPS)ExcellentBook Value Per ShareExcellentDividend Per Share (DPS)AverageCapital Expenditures (CapEx)Excellent| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 25.88 | -24.81 | 2.31 | 34.5 | 27.19 |
| Cash Earnings Per Share (Cash EPS) | 49.69 | 30.56 | 28.44 | 75.31 | 52.38 |
| Book Value Per Share | 332.44 | 337.44 | 339.62 | 390.94 | 443.31 |
| Dividend Per Share (DPS) | 4.94 | 4.98 | 4.94 | 4.74 | 5 |
| Capital Expenditures (CapEx) | 596 | 795 | 888 | 1111 | 1347 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability Score : 4.60The company shows strengths in return on capital employed and return on assets, but gross profit, operating, and net margins are low. This indicates that while the company is generating returns on its investments, its core profitability needs improvement. Enhancing cost management and revenue strategies could significantly boost profitability.
Gross Profit MarginPoorReturn on Capital Employed (ROCE)ExcellentReturn on Equity (ROE)PoorReturn on Assets (ROA)GoodOperating MarginPoorNet MarginPoor| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 12.53 | 3.58 | 7.74 | 11.11 | 9.9 |
| Return on Capital Employed (ROCE) | 10 | 3 | 7 | 10 | 9 |
| Return on Equity (ROE) | 7.76 | -1.2 | 1.34 | 13.37 | 5.61 |
| Return on Assets (ROA) | 11.7 | 7.13 | 7.95 | 9.32 | 8.12 |
| Operating Margin | 18.76 | 12.4 | 13.44 | 16.22 | 15.22 |
| Net Margin | 6.74 | -1.03 | 1.09 | 11.56 | 4.81 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency Score : 4.67The company's efficiency in utilizing its assets is mixed. While days sales in inventory and receivable days are well-managed, the turnover ratios for fixed assets, inventory, receivables, and capital are low. This suggests there is room to improve the efficiency with which the company uses its resources to generate revenue. Efficient asset utilization can lead to better profitability and overall financial health.
Fixed Asset Turnover RatioPoorInventory Turnover RatioPoorReceivables Turnover RatioPoorDays Sales in Inventory RatioExcellentReceivable DaysExcellentCapital Turnover RatioPoor| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.26 | 1.21 | 1.32 | 1.4 | 1.03 |
| Inventory Turnover Ratio | 4.5 | 4.6 | 4.63 | 5.32 | 6.32 |
| Receivables Turnover Ratio | 7.01 | 6.65 | 7.14 | 8 | 8.44 |
| Days Sales in Inventory Ratio | 81.11 | 79.35 | 78.83 | 68.61 | 57.75 |
| Receivable Days | 52.07 | 54.89 | 51.12 | 45.62 | 43.25 |
| Capital Turnover Ratio | 0.76 | 0.72 | 0.76 | 0.83 | 0.79 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Coverage Score : 5.60The company's ability to cover its financial obligations is mixed. While interest coverage is adequate, equity dividend coverage is weak. This suggests the company can comfortably meet its debt obligations, but may struggle to provide strong returns to equity holders through dividends. Balancing debt and equity obligations is crucial for maintaining financial stability and investor confidence.
Interest Coverage RatioGoodEquity Dividend Coverage RatioPoor| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 5.34 | 1.15 | 1.62 | 5.09 | 3.9 |
| Equity Dividend Coverage Ratio | 5.26 | 0.98 | 11.11 | 5 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Solvency Score : 10.00The company's solvency position is very strong, indicating a solid ability to meet long-term obligations. This suggests that the company has a stable capital structure and is less vulnerable to financial distress. This robust solvency can support future growth and investment opportunities.
Debt RatioExcellentDebt to Equity RatioExcellentEquity RatioExcellentDebt To Asset RatioExcellent| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.34 | 0.38 | 0.39 | 0.28 | 0.32 |
| Debt to Equity Ratio | 0.52 | 0.61 | 0.64 | 0.39 | 0.47 |
| Equity Ratio | 0.66 | 0.62 | 0.61 | 0.72 | 0.68 |
| Debt To Asset Ratio | 0.28 | 0.31 | 0.3 | 0.19 | 0.22 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
Liquidity Score : 2.00The company's liquidity position is weak. Maintaining adequate liquidity is crucial for meeting short-term obligations and ensuring operational stability. While a low score suggests potential difficulties in meeting immediate liabilities, it may also reflect a strategic decision to invest more in long-term assets or operations. The company needs to balance its investment strategies with the need for readily available funds.
Current RatioPoorQuick RatioPoorCash RatioPoorOperating Cash Flow RatioPoor| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.04 | 1.82 | 1.65 | 0.96 | 0.88 |
| Quick Ratio | 1.33 | 1.18 | 1.13 | 0.67 | 0.64 |
| Cash Ratio | 0.55 | 0.47 | 0.38 | 0.28 | 0.25 |
| Operating Cash Flow Ratio | 0.47 | 0.31 | 0.39 | 0.28 | 0.24 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Neuland Laboratories Ltd | 7.84 | 61.14 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 2 | Granules India Ltd | 7.73 | 32.77 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 3 | Alembic Pharmaceuticals Ltd | 7.54 | 22.23 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 4 | Syngene International Ltd | 7.44 | 56.08 | Overvalued | 918.00 | 7.55 | 317.00 |
| 5 | Emcure Pharmaceuticals Ltd | 7.40 | 36.42 | Neutral | 1865.00 | 38.66 | 941.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 28.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | ERIS Lifesciences Ltd | 7.15 | 32.39 | Neutral | 1120.00 | 17.61 | 648.00 |
| 8 | Piramal Pharma Ltd | 5.83 | -64.86 | Neutral | 922.00 | 5.27 | -326.00 |
| 9 | Jubilant Pharmova Ltd | 5.71 | 38.62 | Neutral | 1260.00 | 1.25 | 398.00 |
| 10 | Natco Pharma Ltd | 5.69 | 11.22 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 11 | Strides Pharma Science Ltd | 5.55 | 18.41 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | Jeena Sikho Lifecare Ltd | 5.52 | 31.22 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | Wockhardt Ltd | 5.07 | 153.40 | Neutral | 652.00 | 19.51 | 199.00 |
| 14 | Pfizer Ltd | 3.45 | 45.16 | Neutral | -82.00 | 157.92 | 300.00 |
| 15 | Procter & Gamble Health Ltd | 3.45 | 31.71 | Neutral | 457.00 | 196.94 | 327.00 |
| 16 | Sanofi India Ltd | 3.45 | 18.59 | Neutral | 491.00 | 134.52 | 413.00 |
Balanced ManagementJubilant Pharmova's management effectiveness presents a mixed assessment. Strengths include consistent sales growth and recent improvements in compounded profit growth, supported by stable promoter holding. Concerns arise from declining ROCE and ROE, alongside inconsistent dividend payouts. Revenue expansion is clear, but operational efficiency and capital returns require enhancement. Strategic initiatives' impact on financial metrics needs monitoring, along with the increased debt's effect on enterprise value. Management shows a blend of growth and areas needing attention.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (2014-2025) | Consistent growth | Demonstrates sustained revenue expansion. |
| PROS | Promoter Holding | 50.67% | Indicates stable ownership and alignment. |
| CONS | ROCE Trend | Declining | Suggests decreasing efficiency in capital allocation. |
| CONS | Dividend Payout | Inconsistent | May affect investor confidence due to unpredictable returns. |
Financial Performance & GrowthAverageCapital Efficiency & ReturnsWeakFinancial Health & PrudenceAverageShareholding & Ownership StructureGoodFinancial Performance & Growth
Jubilant Pharmova's financial performance is mixed. Sales have grown consistently, but profit growth has been volatile. The OPM % has fluctuated, reflecting inconsistent operational efficiency. While compounded sales growth demonstrates a positive trend, the compounded profit growth has been inconsistent.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Compounded Sales Growth (%) | 7.29 | 6.14 | 6.28 | 6.70 | 7.23 |
| Compounded Profit Growth (%) | 66.28 | 14.78 | -6.5 | 7.3 | 83.6 |
Quarterly sales have generally increased, however, the operating profit margin has seen some fluctuations. Other income has varied, significantly affecting the profit before tax. The company needs to stabilize its profit growth and enhance operational efficiency.
Capital Efficiency & Returns
Capital efficiency and returns on equity for Jubilant Pharmova show concerning trends. ROCE and ROE were healthy in prior years but have declined significantly, indicating a weakened ability to generate returns from capital and shareholder funds.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | ROCE (%) | 10 | 15.33 | 12.33 | 3 | 7 | 10 |
The decline in ROCE and ROE raises concerns about the company's ability to efficiently allocate capital and generate shareholder value.
Financial Health & Prudence
Jubilant Pharmova's financial health and prudence require careful consideration. The company's debt management reveals fluctuating borrowings over the years. The dividend payout has been inconsistent.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Borrowings | 4563 | 3951 | 3609 | 3677 | 3664 | 2731 |
While borrowings have decreased in the most recent year, the overall trend shows variability. The absence of a consistent dividend payout policy may affect investor sentiment. These factors suggest the need for vigilant financial management.
Shareholding & Ownership Structure
The shareholding and ownership structure of Jubilant Pharmova present a mixed picture. Promoter holding remains stable, indicating continued alignment with the company's vision. However, there has been a decrease in FII holding, offset by an increase in DII holding.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter Holding (%) | 54.02 | 50.68 | 50.68 | 50.68 | 50.68 | 50.68 | 50.67 | 50.67 | 50.67 |
| FII Holding (%) | 20.70 | 23.04 | 26.74 | 27.91 | 25.69 | 23.45 | 23.22 | 19.06 | 17.23 |
| DII Holding (%) | 3.72 | 6.00 | 4.78 | 1.87 | 1.28 | 0.63 | 1.62 | 3.77 | 7.05 |
This shift in institutional holding patterns may reflect changing investor sentiment or strategic decisions by these entities.
Balanced RiskThe risk assessment for Jubilant Pharmova shows a moderate level of concern. Promoter holding indicates stability, while other factors raise potential risks. Fluctuations in profitability, coupled with inconsistent ROCE and ROE, suggest operational challenges. Changes in the shareholding pattern, particularly the decrease in FII holding, also warrant attention. Overall, a cautious approach is advisable, considering both the strengths and potential vulnerabilities of the company.
Segment performance volatilityAverageForeign exchange or interest rate exposureAverageRegulatory compliance cost trendsAverageSegment performance volatility
The quarterly results of Jubilant Pharmova show significant volatility in net profit. There are fluctuations in quarterly sales growth, operating profit, and net profit.
| Quarter | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YOY Sales Growth (%) | -3.31 | -11.19 | -3.50 | 18.46 | 9.85 | 9.31 | 5.05 | 8.03 | 4.80 | 9.12 | 4.28 | 8.62 | 9.68 |
| YOY Profit Growth (%) | -73 | -71 | -122 | -131 | -266 | -87 | 301 | 526 | 99 | 1676 | 81 | 73 | 16210 |
This variability indicates potential inconsistencies in segment performance, which could impact overall financial stability.
Foreign exchange or interest rate exposure
Jubilant Pharmova has exposure to interest rate fluctuations, as evidenced by the interest expenses reported quarterly.
| Quarter | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest | 40 | 40 | 42 | 51 | 56 | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 |
The increasing interest expenses indicate a potential risk due to rising interest rates, which could affect profitability.
Regulatory compliance cost trends
The expenses have been increasing every year which implies that regulatory compliance cost trends are also increasing every year.
| Year | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |---|---|---|---|---|---|---|---|---|---|---|---| | Expenses | 4,763 | 5,141 | 4,493 | 4,510 | 5,995 | 7,367 | 4,428 | 4,695 | 4,980 | 5,503 | 5,802 | 6,061 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10971.74Bearish
- SMA 20978.71Bearish
- SMA 50974.90Bearish
- EMA 10971.59Bearish
- EMA 20975.28Bearish
- EMA 50975.86Bearish
- DEMA 10966.36Bearish
- DEMA 20971.69Bearish
- DEMA 50976.78Bearish
- TEMA 10964.58Bullish
- TEMA 20966.69Bearish
- TEMA 50978.12Bearish
- MACD-3.34Bearish
- ADX17.17Weak Trend
- IndicatorValueSignal
- RSI38.42Neutral
- CCI-119.37Oversold
- ROC 9-1.50Bearish
- ROC 14-2.28Bearish
- ROC 25-1.73Bearish
- Stoch K13.65Oversold
- Stoch D18.36Oversold
- IndicatorValueSignal
- BB Upper995.50Neutral
- BB Middle978.71Neutral
- BB Lower961.92Neutral
- ATR8.04Low Volatility
- IndicatorValueSignal
- MFI30.98Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10977.81Bearish
- SMA 20981.45Bearish
- SMA 50971.82Bearish
- EMA 10974.44Bearish
- EMA 20976.00Bearish
- EMA 50975.79Bearish
- DEMA 10970.15Bearish
- DEMA 20976.22Bearish
- DEMA 50975.07Bearish
- TEMA 10965.90Bearish
- TEMA 20974.04Bearish
- TEMA 50973.89Bearish
- MACD-0.61Bearish
- ADX18.46Weak Trend
- IndicatorValueSignal
- RSI41.22Neutral
- CCI-160.24Oversold
- ROC 9-2.76Bearish
- ROC 14-2.67Bearish
- ROC 252.00Bullish
- Stoch K20.07Neutral
- Stoch D22.89Neutral
- IndicatorValueSignal
- BB Upper997.50Neutral
- BB Middle981.45Neutral
- BB Lower965.39Neutral
- ATR11.27Low Volatility
- IndicatorValueSignal
- MFI24.39Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10982.05Bearish
- SMA 20971.68Bearish
- SMA 50983.40Bearish
- EMA 10976.36Bearish
- EMA 20976.16Bearish
- EMA 50973.14Bearish
- DEMA 10976.18Bearish
- DEMA 20975.77Bearish
- DEMA 50988.75Bearish
- TEMA 10973.82Bearish
- TEMA 20977.08Bearish
- TEMA 50N/AN/A
- MACD-0.01Bearish
- ADX13.51Weak Trend
- IndicatorValueSignal
- RSI44.45Neutral
- CCI-30.89Neutral
- ROC 9-2.11Bearish
- ROC 140.16Bullish
- ROC 25-0.59Bearish
- Stoch K49.81Neutral
- Stoch D58.28Neutral
- IndicatorValueSignal
- BB Upper998.56Neutral
- BB Middle971.68Neutral
- BB Lower944.81Neutral
- ATR17.69Low Volatility
- IndicatorValueSignal
- MFI47.85Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10972.88Bullish
- SMA 20981.91Bearish
- SMA 50959.64Bullish
- SMA 100923.68Bullish
- SMA 2001005.76Bearish
- EMA 10978.02Bearish
- EMA 20977.31Bearish
- EMA 50961.47Bullish
- EMA 100960.87Bullish
- EMA 200981.32Bearish
- DEMA 10978.00Bearish
- DEMA 20983.10Bearish
- DEMA 50980.25Bearish
- DEMA 100940.12Bullish
- DEMA 200959.85Bullish
- TEMA 10980.26Bearish
- TEMA 20973.65Bearish
- TEMA 501004.08Bearish
- TEMA 100958.64Bullish
- TEMA 200908.53Bullish
- MACD3.41Bearish
- ADX14.02Weak Trend
- IndicatorValueSignal
- RSI49.79Neutral
- CCI-8.16Neutral
- ROC 14-2.17Bearish
- ROC 25-2.21Bearish
- Stoch K66.16Neutral
- Stoch D68.44Neutral
- IndicatorValueSignal
- BB Upper1014.56Neutral
- BB Middle981.90Neutral
- BB Lower949.25Neutral
- ATR27.39Low Volatility
- IndicatorValueSignal
- MFI40.32Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20917.91Bullish
- SMA 501025.60Bearish
- EMA 20958.33Bullish
- EMA 50981.16Bearish
- DEMA 20942.97Bullish
- DEMA 50978.15Bearish
- TEMA 20964.69Bullish
- TEMA 50914.56Bullish
- MACD-5.65Bullish
- ADX19.82Weak Trend
- IndicatorValueSignal
- RSI49.86Neutral
- CCI-44.69Neutral
- ROC 1419.40Bullish
- ROC 25-10.15Bearish
- Stoch K79.68Neutral
- Stoch D83.11Overbought
- IndicatorValueSignal
- BB Upper1042.37Neutral
- BB Middle917.91Neutral
- BB Lower793.46Neutral
- ATR61.73Low Volatility
- IndicatorValueSignal
- MFI61.16Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6943.26Bullish
- SMA 121029.79Bearish
- SMA 241014.01Bearish
- EMA 6957.08Bullish
- EMA 12978.27Bullish
- EMA 24936.61Bullish
- DEMA 6927.88Bullish
- DEMA 12974.95Bullish
- DEMA 241056.86Bearish
- TEMA 6930.40Bullish
- TEMA 12911.94Bullish
- TEMA 241042.02Bearish
- MACD129.02Bearish
- ADX24.74Weak Trend
- IndicatorValueSignal
- RSI55.10Neutral
- CCI64.49Neutral
- ROC 2547.58Bullish
- ROC 50156.34Bullish
- Stoch K60.57Neutral
- Stoch D74.11Neutral
- IndicatorValueSignal
- BB Upper1288.18Neutral
- BB Middle1037.65Neutral
- BB Lower787.12Neutral
- ATR150.03Low Volatility
- IndicatorValueSignal
- MFI75.10Neutral